

Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/H66DE0E6914EEN.html>

Date: March 2020

Pages: 150

Price: US\$ 2,000.00 (Single User License)

ID: H66DE0E6914EEN

Abstracts

Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2020, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 6, 2, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Hemophilia B (Factor IX Deficiency) - Overview

Hemophilia B (Factor IX Deficiency) - Therapeutics Development

Hemophilia B (Factor IX Deficiency) - Therapeutics Assessment

Hemophilia B (Factor IX Deficiency) - Companies Involved in Therapeutics
Development

Hemophilia B (Factor IX Deficiency) - Drug Profiles

Hemophilia B (Factor IX Deficiency) - Dormant Projects

Hemophilia B (Factor IX Deficiency) - Discontinued Products

Hemophilia B (Factor IX Deficiency) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

- Number of Products under Development for Hemophilia B (Factor IX Deficiency), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by ApcinteX Ltd, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by ASC Therapeutics Inc, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by Catalyst Biosciences Inc, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by China Biologic Products Holdings Inc, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
- Hemophilia B (Factor IX Deficiency) - Pipeline by Expression Therapeutics LLC, H1 2020
- Hemophilia B (Factor IX Deficiency) - Dormant Projects, H1 2020
- Hemophilia B (Factor IX Deficiency) - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Hemophilia B (Factor IX Deficiency) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hemophilia B (Factor IX Deficiency), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

ApcinteX Ltd

ASC Therapeutics Inc

Catalyst Biosciences Inc

Chengdu Rongsheng Pharmaceutical Co Ltd

China Biologic Products Holdings Inc

Daiichi Sankyo Co Ltd

Expression Therapeutics LLC

Freeline Therapeutics Ltd

GC Pharma

Genzyme Corp

Intellia Therapeutics Inc

LFB SA

Logicbio Therapeutics Inc

OPKO Health Inc

Pfizer Inc

RegenxBio Inc

Sangamo Therapeutics Inc

Sanofi

Shenzhen Weiwu Guangming Biological Preparations Co Ltd

Sigilon Therapeutics Inc

Takeda Pharmaceutical Co Ltd
UBI Pharma Inc
UniQure NV

I would like to order

Product name: Hemophilia B (Factor IX Deficiency) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/H66DE0E6914EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H66DE0E6914EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970